ArticleScientific reports2026
sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
B7 homolog 3 protein (B7-H3), a member of the B7 checkpoint family, is aberrantly and consistently expressed on the membranes of various human cancer cells and is associated with poor prognosis. Emerging evidence also indicates that soluble B7-H3 (sB7-H3) correlates with adverse outcomes in multiple malignancies. In this study, we measured sB7-H3 levels in peripheral blood using an enzyme-linked immunosorbent assay (ELISA) from 100 newly diagnosed osteosarcoma (OTS) patients, both before and after neoadjuvant chemotherapy, and simultaneously assessed B7-H3 tissue expression via immunohistochemistry (IHC) analysis of surgical specimens. Our analysis showed significant associations between B7-H3 tissue expression and histopathological response to chemotherapy, with the H-score threshold > 75 identifying patients with particularly poor prognosis (p < 0.05). Although no significant correlation was observed between tissue and circulating B7-H3 expression, we found that lower baseline sB7-H3 levels (pre-sB7H3 < 21.2425 ng/mL) predicted poor clinical outcomes. By integrating sB7-H3 levels with established prognostic indicators, including metastatic status and lactate dehydrogenase (LDH) levels, we developed a comprehensive prognostic model that demonstrated strong predictive accuracy for survival outcomes. Notably, pre-sB7-H3 levels were significantly associated with good histological responses (p < 0.05). Longitudinal monitoring during treatment revealed that dynamic changes in sB7-H3 levels positively correlated with disease progression (p < 0.05) and inversely correlated with good histological responses (p < 0.05). These findings highlight serum sB7-H3 as a clinically valuable biomarker in OTS, providing prognostic information both at diagnosis and throughout the course of treatment in a relatively convenient manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.